COMPASS Pathways Plc American Depository Shares (CMPS) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
COMPASS Pathways Plc American Depository Shares (CMPS) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 87.3% versus a loss of 11.1%. Over five years, STOK leads with a +3.3% price change compared with -63.7% for CMPS. COMPASS Pathways Plc American Depository Shares is the larger company by market cap ($1.56 billion vs $1.53 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPS | STOK |
|---|---|---|
| Share price | $11.28 | $23.77 |
| Market cap | $1.56B | $1.53B |
| 1-day change | -3.53% | -2.14% |
| YTD return | +69.42% | -23.47% |
| 1-year return | +87.34% | -11.06% |
| 5-year return | -63.72% | +3.27% |
| EPS (TTM) | $-3.76 | $-3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.87 | $40.22 |
| 52-week low | $4.88 | $20.32 |
| Distance from 52-week high | -28.94% | -40.90% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +110.60% | +95.46% |
| Average volume | 3.04M | 852.03K |
| Shares outstanding | 138.48M | 64.53M |
| Employees | 156 | 170 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CMPS has outperformed STOK by 98.4 percentage points over the past year.
About COMPASS Pathways Plc American Depository Shares
CMPS stock →COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 156 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
CMPS vs STOK FAQ
Which is bigger, COMPASS Pathways Plc American Depository Shares or Stoke Therapeutics?
COMPASS Pathways Plc American Depository Shares (CMPS) is larger, with a market capitalization of $1.56B compared with $1.53B for Stoke Therapeutics (STOK).
Which stock has performed better over the past year, CMPS or STOK?
CMPS returned +87.34% over the past 12 months, compared with -11.06% for STOK (price return, excluding dividends). Past performance does not predict future results.
Are COMPASS Pathways Plc American Depository Shares and Stoke Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.